Raymond James & Associates Trans Medics Group, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Trans Medics Group, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 27,436 shares of TMDX stock, worth $1.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,436

Previous 23,444 17.03%

Holding current value

$1.9 Million

Previous $3.53 Million 21.98%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$135.68 - $176.11 $541,634 - $703,031	3,992 Added 17.03%	27,436 $4.31 Million
Q2 2024 Jul 19, 2024	BUY	$72.62 - $150.62 $1.03 Million - $2.13 Million	14,156 Added 152.41%	23,444 $3.53 Million
Q1 2024 Apr 22, 2024	BUY	$70.86 - $89.93 $332,687 - $422,221	4,695 Added 102.22%	9,288 $686,000
Q4 2023 Jan 16, 2024	BUY	$36.74 - $81.08 $31,265 - $68,999	851 Added 22.74%	4,593 $362,000
Q3 2023 Oct 24, 2023	SELL	$53.47 - $96.07 $111,164 - $199,729	-2,079 Reduced 35.72%	3,742 $204,000
Q2 2023 Jul 25, 2023	SELL	$66.23 - $88.73 $957,487 - $1.28 Million	-14,457 Reduced 71.29%	5,821 $488,000
Q1 2023 Apr 14, 2023	BUY	$53.63 - $82.33 $702,231 - $1.08 Million	13,094 Added 182.27%	20,278 $1.54 Million
Q4 2022 Feb 08, 2023	BUY	$39.08 - $64.29 $66,826 - $109,935	1,710 Added 31.24%	7,184 $443,000
Q3 2022 Oct 25, 2022	BUY	$31.56 - $55.75 $172,759 - $305,175	5,474 New	5,474 $228,000
Q2 2021 Aug 11, 2021	SELL	$21.63 - $40.07 $185,909 - $344,401	-8,595 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$17.75 - $47.82 $152,561 - $411,012	8,595 New	8,595 $357,000

Others Institutions Holding TMDX

# of Institutions

397

Shares Held

31.7M

Call Options Held

466K

Put Options Held

286K

View Full List

About TransMedics Group, Inc.

Ticker TMDX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 31,831,400
Market Cap $2.2B
Description
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and custo...

More about TMDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Trans Medics Group, Inc. Transaction History